Immunoreactivity against SLC3A2 in high grade gliomas displays positive correlation with glioblastoma patient survival: Potential target for glioma diagnosis and therapy
N. Karakas, O. Topcu, E. Tuzun, O. Timirci Kahraman, P. A. Sabanci, Y. Aras, B. Yetimler, G. Unverengil, M. B. Bilgic, K. Shah, H. Korkaya
The paper identifies SLC3A2 as an autoantigen in high-grade gliomas, showing its immunoreactivity correlates with improved patient survival.
bioRxiv · Jan 26, 2023 · PreprintImmunology